Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (35) 35
humans (29) 29
oncology (24) 24
female (22) 22
male (22) 22
middle aged (16) 16
tumors (13) 13
aged (12) 12
prognosis (12) 12
adult (11) 11
cancer (11) 11
chemotherapy (11) 11
survival (11) 11
disease-free survival (9) 9
epidemiology (9) 9
medical research (9) 9
patients (9) 9
metastasis (8) 8
analysis (7) 7
clinical trials (7) 7
risk factors (7) 7
treatment outcome (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
chemotherapy, adjuvant (6) 6
cisplatin (6) 6
hematology, oncology and palliative medicine (6) 6
lung neoplasms - drug therapy (6) 6
medical prognosis (6) 6
original reports (6) 6
studies (6) 6
survival analysis (6) 6
vinorelbine plus cisplatin (6) 6
care and treatment (5) 5
children (5) 5
clinical medicine (5) 5
clinical-trials (5) 5
diagnosis (5) 5
expression (5) 5
kaplan-meier estimate (5) 5
medicine, experimental (5) 5
proportional hazards models (5) 5
retrospective studies (5) 5
thromboembolism (5) 5
age (4) 4
aged, 80 and over (4) 4
antineoplastic agents - therapeutic use (4) 4
bayesian analysis (4) 4
biomarkers (4) 4
biomarkers, tumor - genetics (4) 4
cancer therapies (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
carcinoma, non-small-cell lung - genetics (4) 4
life sciences (4) 4
lung neoplasms - genetics (4) 4
lung neoplasms - mortality (4) 4
lung neoplasms - pathology (4) 4
medical informatics (4) 4
mutation (4) 4
neoplasm staging (4) 4
pediatrics (4) 4
randomized controlled trials as topic (4) 4
survival rate (4) 4
toxicity (4) 4
trial (4) 4
young adult (4) 4
adjuvant chemotherapy (3) 3
adolescent (3) 3
age factors (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
cancer and oncology (3) 3
cancer och onkologi (3) 3
carcinoma (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
cyclophosphamide (3) 3
disease (3) 3
disease progression (3) 3
efficacy (3) 3
etoposide (3) 3
follow-up (3) 3
follow-up studies (3) 3
france (3) 3
gene expression (3) 3
genes (3) 3
genetic aspects (3) 3
ifosfamide (3) 3
incidence (3) 3
infant (3) 3
intensive induction (3) 3
klinisk medicin (3) 3
medical and health sciences (3) 3
medicin och hälsovetenskap (3) 3
medicine (3) 3
medicine, research & experimental (3) 3
metastases (3) 3
microrna (3) 3
pooled analysis (3) 3
predictive value of tests (3) 3
public, environmental & occupational health (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Erratum to: “The frequency of cancer in France: Most recent data and trends” (Bulletin du Cancer 104(1) (2017) 20–29) (S0007455116303149) (10.1016/j.bulcan.2016.11.003)
by Ribassin-Majed, Laureen and Le Teuff, Gwénaël and Hill, Catherine
Bulletin du Cancer, ISSN 0007-4551, 04/2017, Volume 104, Issue 4, p. 388
Dans le numéro 1, volume 104, p. 20–29 du Bulletin du Cancer, une erreur est survenue dans l'orthographe du nom de l'un des auteurs. Il fallait lire Gwénaël Le... 
Journal Article
Details down arrow
2. Erratum to: "The frequency of cancer in France: Most recent data and trends" [Bull. Cancer 104 (2017) 20-29
by Ribassin-Majed, Laureen and Le Teuff, Gwénaël and Hill, Catherine
Bulletin du cancer, 04/2017, Volume 104, Issue 4, p. 388
Journal Article
Details down arrow
3. Full Text Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study
by Brard, C and Hampson, LV and Gaspar, N and Le Deley, MC and Le Teuff, G
BMC MEDICAL RESEARCH METHODOLOGY, ISSN 1471-2288, 04/2019, Volume 19, Issue 1, pp. 85 - 17
BackgroundPerforming well-powered randomised controlled trials (RCTs) of new treatments for rare diseases is often infeasible. However, with the increasing... 
PROPORTIONAL-HAZARDS | RARE DISEASES | Aggregate treatment effect | INFORMATION | Mixture prior | Individual control data | ANALYTIC-PREDICTIVE PRIORS | PRIOR-DATA CONFLICT | CHEMOTHERAPY | Simulation study | PRIOR DISTRIBUTIONS | Rare disease | CLINICAL-TRIALS | HEALTH CARE SCIENCES & SERVICES | Power prior | Bayesian randomised survival trial | OSTEOSARCOMA | MURAMYL TRIPEPTIDE | Rare diseases | Clinical trials | Evaluation | Care and treatment | Methods | Biometrics | Economic models | Bone cancer | Chemotherapy | Health care policy | Systematic review | Random variables | Patients | Bayesian analysis | Life Sciences | Pharmaceutical sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation
by Derosa, Lisa and Bayar, Mohamed Amine and Albiges, Laurence and Le Teuff, Gwénaël and Escudier, Bernard
Angiogenesis, ISSN 0969-6970, 8/2019, Volume 22, Issue 3, pp. 383 - 395
In patients with metastatic renal cell carcinoma (mRCC), the oncologic benefit of second-line treatment for high volume tumors or presence of more than five... 
Biomedicine, general | Metastatic renal cell carcinoma | Second line | IMDC | Prognostic model | MSKCC | Oncology | Cell Biology | Tumor burden | Biomedicine | Cancer Research | Time from first to second line | Ophthalmology | Cardiology | TARGETED THERAPY | SORAFENIB | DEPENDENCE | TRIAL | SUNITINIB | PERIPHERAL VASCULAR DISEASE | Medical research | Classification schemes | Cell survival | Risk groups | Decision making | Clinical trials | Metastasis | Calibration | Risk analysis | Survival | Patients | Two phase | Risk factors | Metastases | Medical prognosis | Kidney cancer | Classification | Clear cell-type renal cell carcinoma | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method
by Bayar, Mohamed Amine and Ivanova, Anastasia and Le Teuff, Gwénaël
Computer Methods and Programs in Biomedicine, ISSN 0169-2607, 07/2019, Volume 176, pp. 211 - 223
The continual reassessment method (CRM) is a model-based dose-finding design for single-agent phase I oncology trials. With the advance of targeted therapies... 
Dose-finding | Drug combinations | SAS MCMC procedure | Continual reassessment method | Phase I clinical trial | CRM | DESIGN | MEDICAL INFORMATICS | ENGINEERING, BIOMEDICAL | PHASE-I TRIALS | COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS | ONCOLOGY | CLINICAL-TRIALS | R-PACKAGE | COMPUTER SCIENCE, THEORY & METHODS | DRUG-COMBINATION | Analysis | Methods | Drug therapy, Combination
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma
by Brard, Caroline and Piperno-Neumann, Sophie and Delaye, Jessy and Brugières, Laurence and Hampson, Lisa V and Le Teuff, Gwénaël and Le Deley, Marie-Cécile and Gaspar, Nathalie
BMJ Open, ISSN 2044-6055, 05/2019, Volume 9, Issue 5, p. e025877
IntroductionThe controversial results on the mifamurtide efficacy associated with chemotherapy, issued from the American INT-0133-study, in localised... 
SURVIVAL | PHOSPHATIDYLETHANOLAMINE | MEDICINE, GENERAL & INTERNAL | LIPOSOMAL MURAMYL TRIPEPTIDE | MACROPHAGES | MONOCYTE ACTIVATION | CLINICAL-TRIALS | DOXORUBICIN | METHOTREXATE | COMBINATION | IFOSFAMIDE | Studies | Bone cancer | Chemotherapy | Medical prognosis | Clinical trials | Oncology | Metastasis | Kinases | Cancer therapies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study
by Bayar, Mohamed Amine and Le Teuff, Gwénaël and Koenig, Franz and Le Deley, Marie-Cécile and Michiels, Stefan
Statistical Methods in Medical Research, ISSN 0962-2802, 07/2019, p. 96228021986231
In rare diseases, fully powered large trials may not be doable in a reasonable time frame even with international collaborations. In a previous work, we... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
by Frances A. Shepherd and Caroline Domerg and Pierre Hainaut and Pasi A. Jänne and Jean-Pierre Pignon and Stephen Graziano and Jean-Yves Douillard and Elizabeth Brambilla and Thierry Le Chevalier and Lesley Seymour and Abderrahmane Bourredjem and Gwénaël Le Teuff and Robert Pirker and Martin Filipits and Rafael Rosell and Robert Kratzke and Bizhan Bandarchi and Xiaoli Ma and Marzia Capelletti and Jean-Charles Soria and Ming-Sound Tsao
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 17, pp. 2173 - 2181
Purpose We undertook this analysis of KRAS mutation in four trials of adjuvant chemotherapy (ACT) versus observation (OBS) to clarify the prognostic/predictive... 
GROWTH-FACTOR RECEPTOR | ACTIVATION | K-RAS ONCOGENE | VINORELBINE PLUS CISPLATIN | ONCOLOGY | MARKER | COLORECTAL-CANCER | ADENOCARCINOMA | PHASE-III | MOLECULAR BIOMARKERS | EGFR | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Carcinoma, Non-Small-Cell Lung - genetics | Gene Pool | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Chemotherapy, Adjuvant | Mutation | Genes, ras | Neoplasm Staging | Thor3 | Thor12 | ORIGINAL REPORTS | To2 | Thor5 | To20
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. La fréquence des cancers en 2016 et leur évolution
by Ribassin-Majed, Laureen and Le-Teuff, Gwénaël and Hill, Catherine
Bulletin du Cancer, ISSN 0007-4551, 01/2017, Volume 104, Issue 1, pp. 20 - 29
We present and discuss recent data on the frequency of cancer in France and on cancer survival. In the male population, the incidence of prostate and head and... 
Mortality | France | Epidemiology | Survival | Cancer | Incidence
Journal Article
Details down arrow
10. Corrigendum to “Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours” [Eur J Cancer 69 (2016) 151–157]
by Marco Gizzi and Lucie Oberic and Christophe Massard and Audrey Poterie and Gwenael Le Teuff and Yohann Loriot and Laurence Albiges and Giulia Baciarello and Judith Michels and Alberto Bossi and Pierre Blanchard and Bernard Escudier and Karim Fizazi
European Journal of Cancer, ISSN 0959-8049, 04/2017, Volume 75, p. 333
Chemotherapy | Thromboembolism | Cisplatin | Tumors | Cancer
Journal Article
Details down arrow
11. Full Text ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
by Friboulet, Luc and Olaussen, Ken André and Pignon, Jean-Pierre and Shepherd, Frances A and Tsao, Ming-Sound and Graziano, Stephen and Kratzke, Robert and Douillard, Jean-Yves and Seymour, Lesley and Pirker, Robert and Filipits, Martin and André, Fabrice and Solary, Eric and Ponsonnailles, Florence and Robin, Angélique and Stoclin, Annabelle and Dorvault, Nicolas and Commo, Frédéric and Adam, Julien and Vanhecke, Elsa and Saulnier, Patrick and Thomale, Jürgen and Le Chevalier, Thierry and Dunant, Ariane and Rousseau, Vanessa and Le Teuff, Gwénaël and Brambilla, Elisabeth and Soria, Jean-Charles
The New England Journal of Medicine, ISSN 0028-4793, 03/2013, Volume 368, Issue 12, pp. 1101 - 1110
Earlier studies suggested that the response to platinum treatment in lung cancer might be predicted according to the presence or absence of the DNA repair... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | RRM1 | COMPLEMENTATION GROUP 1 | MESSENGER-RNA EXPRESSION | VALIDATION | MONOCLONAL-ANTIBODIES | III BETA-TUBULIN | CHEMOTHERAPY | Epitope Mapping | Lung Neoplasms - drug therapy | Endonucleases - genetics | Lung Neoplasms - mortality | Humans | Immunoglobulin G | Antineoplastic Agents - therapeutic use | Endonucleases - metabolism | DNA-Binding Proteins - metabolism | Protein Isoforms - metabolism | DNA, Neoplasm | Biomarkers, Tumor - metabolism | Chemotherapy, Adjuvant | Lung Neoplasms - genetics | DNA-Binding Proteins - immunology | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Endonucleases - immunology | Epitopes | DNA-Binding Proteins - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Drug Resistance, Neoplasm - genetics | Cisplatin - therapeutic use | DNA Repair | Carcinoma, Non-Small-Cell Lung - drug therapy | Protein Isoforms - genetics | Usage | Diagnostic immunohistochemistry | Causes of | Genetic aspects | Research | Diagnosis | Gene expression | Lung cancer, Non-small cell | DNA repair | Care and treatment | Lung cancer, Small cell | Health aspects | Cisplatin | Decision making | Lung cancer | DNA damage | Discordance | Clinical trials | Antibodies | Non-small cell lung carcinoma | Nucleotide excision repair | Proteins | Chemotherapy | Lungs | Platinum | Isoforms | Biomarkers | ERCC1 protein | Deoxyribonucleic acid--DNA | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study
: A new strategy for clinical trial design in rare diseases
by Bayar, Mohamed Amine and Le Teuff, Gwénaël and Michiels, Stefan and Sargent, Daniel J and Le Deley, Marie-Cécile
Statistics in Medicine, ISSN 0277-6715, 08/2016, Volume 35, Issue 19, pp. 3245 - 3258
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours
by Marco Gizzi and Lucie Oberic and Christophe Massard and Audrey Poterie and Gwenael Le Teuff and Yohann Loriot and Laurence Albiges and Giulia Baciarello and Judith Michels and Alberto Bossi and Pierre Blanchard and Bernard Escudier and Karim Fizazi
European Journal of Cancer, ISSN 0959-8049, 12/2016, Volume 69, p. 151
Abstract Background: Patients with germ cell tumours (GCT) receiving cisplatin-based chemotherapy are at high risk of thromboembolic events (TEE). Previously,... 
Anticoagulants | Medical treatment | Prophylaxis | Lactate dehydrogenase | Thrombophlebitis | Risk analysis | Patients | Thrombosis | Cisplatin | L-Lactate dehydrogenase | Molecular chains | Risk factors | Studies | Chemotherapy | Lactic acid | Heparin | Thromboembolism | Surface area | Tumors
Journal Article
Details down arrow
14. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours
by Marco Gizzi and Lucie Oberic and Christophe Massard and Audrey Poterie and Gwenael Le Teuff and Yohann Loriot and Laurence Albiges and Giulia Baciarello and Judith Michels and Alberto Bossi and Pierre Blanchard and Bernard Escudier and Karim Fizazi
European Journal of Cancer, ISSN 0959-8049, 12/2016, Volume 69, p. 151
Background: Patients with germ cell tumours (GCT) receiving cisplatin-based chemotherapy are at high risk of thromboembolic events (TEE). Previously, we... 
Anticoagulants | Dehydrogenases | Prophylaxis | Lactate dehydrogenase | Risk analysis | Thrombosis | Patients | Cisplatin | L-Lactate dehydrogenase | Risk factors | Chemotherapy | Platinum | Lactic acid | Heparin | Thromboembolism | Surface area | Tumors
Journal Article
Details down arrow
15. Full Text Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection
by Tsao, Ming-Sound and Marguet, Sophie and Le Teuff, Gwénaël and Lantuejoul, Sylvie and Shepherd, Frances A and Seymour, Lesley and Kratzke, Robert and Graziano, Stephen L and Popper, Helmut H and Rosell, Rafael and Douillard, Jean-Yves and Le-Chevalier, Thierry and Pignon, Jean-Pierre and Soria, Jean-Charles and Brambilla, Elisabeth M
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 30, pp. 3439 - 3446
Purpose The classification for invasive lung adenocarcinoma by the International Association for the Study of Lung Cancer, American Thoracic Society, European... 
SURVIVAL | TRIALS | PULMONARY ADENOCARCINOMAS | VINORELBINE PLUS CISPLATIN | IASLC/ATS/ERS CLASSIFICATION | ONCOLOGY | DISEASE | INTERNATIONAL-ASSOCIATION | POOLED ANALYSIS | PROGNOSTIC VALUE | CANCER | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Prognosis | Adenocarcinoma of Lung | Adenocarcinoma - classification | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Survival Rate | Adenocarcinoma - drug therapy | Lung Neoplasms - classification | Female | Lung Neoplasms - surgery | Aged | Chemotherapy, Adjuvant | Adenocarcinoma - surgery | Thor9 | Thor2 | Thor3 | ORIGINAL REPORTS | Thor5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer
by Brambilla, Elisabeth and Le Teuff, Gwénaël and Marguet, Sophie and Lantuejoul, Sylvie and Dunant, Ariane and Graziano, Stephen and Pirker, Robert and Douillard, Jean-Yves and Le Chevalier, Thierry and Filipits, Martin and Rosell, Rafael and Kratzke, Robert and Popper, Helmut and Soria, Jean-Charles and Shepherd, Frances A and Seymour, Lesley and Tsao, Ming Sound
Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 11, pp. 1223 - 1230
Purpose Tumor lymphocytic infiltration (TLI) has differing prognostic value among various cancers. The objective of this study was to assess the effect of TLI... 
BREAST-CANCER | SURVIVAL | DENSITY | VINORELBINE PLUS CISPLATIN | ONCOLOGY | RECOMMENDATIONS | FAVORABLE PROGNOSIS | RECURRENCE | EXPRESSION | CARCINOMA | CD8(+) T-CELLS | Lung Neoplasms - drug therapy | Predictive Value of Tests | Prognosis | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Reproducibility of Results | Carcinoma, Non-Small-Cell Lung - surgery | Kaplan-Meier Estimate | Proportional Hazards Models | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Lymphocytes, Tumor-Infiltrating - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lung Neoplasms - surgery | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | ORIGINAL REPORTS | Thor9 | To6
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Impact of angiotensin system inhibitors (ASI) on outcome in sunitinib (SU)- treated patients for metastatic renal cell carcinoma (mRCC): Gustave Roussy experience
by Derosa, Lisa and Izzedine, Hassane and Le Teuff, Gwenael and Albiges, Laurence and Escudier, Bernard
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. 4584 - 4584
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Pre-existing hypertension is an independent prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib (SU)
by Derosa, Lisa and Izzedine, Hassane and Le Teuff, Gwenael and Albiges, Laurence and Escudier, Bernard
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. 4573 - 4573
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study
by Bayar, Mohamed Amine and Le Teuff, Gwénaël and Koenig, Franz and Le Deley, Marie-Cécile and Michiels, Stefan
Statistical methods in medical research, 07/2019, p. 962280219862313
In rare diseases, fully powered large trials may not be doable in a reasonable time frame even with international collaborations. In a previous work, we... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Mesenchymal transition and pdgfra amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas
by Puget, Stephanie and Philippe, Cathy and Bax, Dorine A and Job, Bastien and Varlet, Pascale and Junier, Marie-Pierre and Andreiuolo, Felipe and Carvalho, Dina and Reis, Ricardo and Guerrini-Rousseau, Lea and Roujeau, Thomas and Dessen, Philippe and Richon, Catherine and Lazar, Vladimir and Teuff, Gwenael and Sainte-Rose, Christian and Geoerger, Birgit and Vassal, Gilles and Jones, Chris and Grill, Jacques
PLoS ONE, ISSN 1932-6203, 02/2012, Volume 7, Issue 2, p. e30313
Diffuse intrinsic pontine glioma (DIPG) is one of the most frequent malignant pediatric brain tumor and its prognosis is universaly fatal. No significant... 
CELLS | MULTIDISCIPLINARY SCIENCES | TUMOR CONSORTIUM | GROWTH-FACTOR | BRAIN-STEM GLIOMAS | RECURRENT MALIGNANT GLIOMAS | STEREOTACTIC BIOPSY | EXPRESSION | IMATINIB MESYLATE | COPY NUMBER ABERRATIONS | CHILDREN | Immunohistochemistry | Receptor, Platelet-Derived Growth Factor alpha - metabolism | Brain Stem Neoplasms - pathology | Humans | Gene Expression Profiling - methods | Signal Transduction - genetics | Transcription Factors - genetics | Epithelial-Mesenchymal Transition - genetics | Brain Stem Neoplasms - metabolism | Transcription Factors - metabolism | Brain Stem Neoplasms - genetics | Receptor, Platelet-Derived Growth Factor alpha - genetics | Mutation | In Vitro Techniques | Snail Family Transcription Factors | Pediatrics | Platelet-derived growth factor | Gliomas | Genes | Brain tumors | Stem cells | Cellular signal transduction | Genetic transcription | Brain | Health sciences | Profiling | Transcription | Mesenchyme | Neuropathology | Brain stem | Genomics | Leukemia | Brain cancer | Oncology | Genomes | Neurosurgery | Kinases | Paraffin | Cancer therapies | Subgroups | Angiogenesis | Regression models | Missense mutation | Blood platelets | Blood-brain barrier | Thalamus | Diagnosis | Growth factors | Bioinformatics | Deoxyribonucleic acid--DNA | Medical research | Breast cancer | Radiation therapy | Gene expression | Patients | Amplification | Brain research | Glioma | Biopsy | Medical prognosis | Transduction | Tumors | Life Sciences | Neurons and Cognition | Deoxyribonucleic acid | DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.